BIA-Brukerstyrt innovasjonsarena
Diagnostic method to enable targeted therapy of patients with acute myeloid leukemia
The innovation planned in this proposal is a diagnostic method to enable targeted therapy of patients with acute myeloid leukemia (AML) with Clavis Pharma's drug Elacytarabine.
Today's standard treatment for AML, ara-C, is dependent on a nucleoside trans porter (hENT1) in the cell membrane to be...